Inflammatix, Inc.

📍 Sunnyvale, United States🗓 Founded 2016👥 74 employees💰 Last funded Apr 2024
Biotechnology Research🌐 inflammatix.com
Website LinkedIn
Inflammatix is advancing emergency and critical care medicine by leveraging the body’s immune response to support timely, informed decision-making for patients with suspected acute infection or sepsis. TriVerity™ is an FDA-cleared, rapid blood test that applies AI-driven analysis of immune mRNA expression to deliver three results in approximately 30 minutes: likelihood of bacterial infection, likelihood of viral infection, and risk of near-term clinical deterioration. By reducing diagnostic uncertainty early in the patient encounter, TriVerity supports risk stratification and clinical assessment in the emergency department, helping clinicians better understand which patients may require closer monitoring or inpatient care and which patients may be appropriate for lower-acuity pathways. Inflammatix translates immune response data into real-time clinical insights designed to support high-quality care delivery while aligning with health system priorities around operational efficiency, antimicrobial stewardship, and value-based performance.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
United Kingdom
1
Frequently asked questions
Who invested in Inflammatix, Inc.?
Inflammatix, Inc. has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Inflammatix, Inc. last raise funding?
The most recent investment in Inflammatix, Inc. recorded on gritt.io was in April 2024.
When was Inflammatix, Inc. founded?
Inflammatix, Inc. was founded in 2016.
What industry is Inflammatix, Inc. in?
Inflammatix, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Inflammatix, Inc. based?
Inflammatix, Inc. is headquartered in Sunnyvale, United States.